114 related articles for article (PubMed ID: 16109476)
21. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
22. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation.
Roidl A; Berger HJ; Kumar S; Bange J; Knyazev P; Ullrich A
Clin Cancer Res; 2009 Mar; 15(6):2058-66. PubMed ID: 19240166
[TBL] [Abstract][Full Text] [Related]
23. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
da Costa Andrade VC; Parise O; Hors CP; de Melo Martins PC; Silva AP; Garicochea B
Exp Mol Pathol; 2007 Feb; 82(1):53-7. PubMed ID: 17084840
[TBL] [Abstract][Full Text] [Related]
24. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
[TBL] [Abstract][Full Text] [Related]
25. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells.
Jones JL; Shaw JA; Pringle JH; Walker RA
J Pathol; 2003 Dec; 201(4):562-72. PubMed ID: 14648659
[TBL] [Abstract][Full Text] [Related]
26. Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway.
Kasper G; Reule M; Tschirschmann M; Dankert N; Stout-Weider K; Lauster R; Schrock E; Mennerich D; Duda GN; Lehmann KE
BMC Cancer; 2007 Jan; 7():12. PubMed ID: 17233884
[TBL] [Abstract][Full Text] [Related]
27. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
Matakidou A; El Galta R; Rudd MF; Webb EL; Bridle H; Eisen T; Houlston RS
Br J Cancer; 2007 Jun; 96(12):1904-7. PubMed ID: 17519899
[TBL] [Abstract][Full Text] [Related]
28. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness.
Götte M; Mohr C; Koo CY; Stock C; Vaske AK; Viola M; Ibrahim SA; Peddibhotla S; Teng YH; Low JY; Ebnet K; Kiesel L; Yip GW
Oncogene; 2010 Dec; 29(50):6569-80. PubMed ID: 20818426
[TBL] [Abstract][Full Text] [Related]
29.
Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
[TBL] [Abstract][Full Text] [Related]
30. FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Chan KM; Zhou Z; Alitalo K; Taipale J; Keski-Oja J; Lehti K
Proc Natl Acad Sci U S A; 2010 Sep; 107(36):15786-91. PubMed ID: 20798051
[TBL] [Abstract][Full Text] [Related]
31. FGFR4 polymorphic variants modulate phenotypic features of Cushing disease.
Nakano-Tateno T; Tateno T; Hlaing MM; Zheng L; Yoshimoto K; Yamada S; Asa SL; Ezzat S
Mol Endocrinol; 2014 Apr; 28(4):525-33. PubMed ID: 24625004
[TBL] [Abstract][Full Text] [Related]
32. Sphingosine-1-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors.
Wang F; Van Brocklyn JR; Edsall L; Nava VE; Spiegel S
Cancer Res; 1999 Dec; 59(24):6185-91. PubMed ID: 10626811
[TBL] [Abstract][Full Text] [Related]
33. Biochemical regulation of breast cancer cell expression of S1P2 (Edg-5) and S1P3 (Edg-3) G protein-coupled receptors for sphingosine 1-phosphate.
Dolezalova H; Shankar G; Huang MC; Bikle DD; Goetzl EJ
J Cell Biochem; 2003 Mar; 88(4):732-43. PubMed ID: 12577307
[TBL] [Abstract][Full Text] [Related]
34. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
[TBL] [Abstract][Full Text] [Related]
35. Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDA-MB-231 human breast cancer cell line.
Pontillo CA; García MA; Peña D; Cocca C; Chiappini F; Alvarez L; Kleiman de Pisarev D; Randi AS
Toxicol Sci; 2011 Apr; 120(2):284-96. PubMed ID: 21205633
[TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression.
Ye YW; Zhou Y; Yuan L; Wang CM; Du CY; Zhou XY; Zheng BQ; Cao X; Sun MH; Fu H; Shi YQ
Cancer; 2011 Dec; 117(23):5304-13. PubMed ID: 21567388
[TBL] [Abstract][Full Text] [Related]
37. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
Ezzat S; Zheng L; Winer D; Asa SL
Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis.
Li DQ; Hou YF; Wu J; Chen Y; Lu JS; Di GH; Ou ZL; Shen ZZ; Ding J; Shao ZM
Eur J Cancer; 2006 Dec; 42(18):3274-86. PubMed ID: 16979889
[TBL] [Abstract][Full Text] [Related]
39. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.
Lee WJ; Chen WK; Wang CJ; Lin WL; Tseng TH
Toxicol Appl Pharmacol; 2008 Jan; 226(2):178-91. PubMed ID: 17961621
[TBL] [Abstract][Full Text] [Related]
40. Curcumin inhibition of integrin (alpha6beta4)-dependent breast cancer cell motility and invasion.
Kim HI; Huang H; Cheepala S; Huang S; Chung J
Cancer Prev Res (Phila); 2008 Oct; 1(5):385-91. PubMed ID: 19138983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]